



Laboratory validation of a clinical metagenomic sequencing assay for pathogen detection in cerebrospinal fluid

Steve Miller, Samia N. Naccache, Erik Samayoa, et al.

Genome Res. 2019 29: 831-842 originally published online April 16, 2019

Access the most recent version at doi:[10.1101/gr.238170.118](https://doi.org/10.1101/gr.238170.118)

References This article cites 40 articles, 8 of which can be accessed free at:
<http://genome.cshlp.org/content/29/5/831.full.html#ref-list-1>

Open Access Freely available online through the *Genome Research* Open Access option.

Creative Commons License This article, published in *Genome Research*, is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at <http://creativecommons.org/licenses/by-nc/4.0/>.

Email Alerting Service Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).

To subscribe to *Genome Research* go to:
<https://genome.cshlp.org/subscriptions>

Method

Laboratory validation of a clinical metagenomic sequencing assay for pathogen detection in cerebrospinal fluid

Steve Miller,^{1,2,10} Samia N. Naccache,^{1,2,3,10} Erik Samayoa,¹ Kevin Messacar,⁴ Shaun Arevalo,^{1,2} Scot Federman,^{1,2} Doug Stryke,^{1,2} Elizabeth Pham,¹ Becky Fung,¹ William J. Bolosky,⁵ Danielle Ingebrigtsen,¹ Walter Lorizio,¹ Sandra M. Paff,¹ John A. Leake,⁶ Rick Pesano,⁶ Roberta DeBiasi,^{7,8} Samuel Dominguez,⁴ and Charles Y. Chiu^{1,2,9}

¹Department of Laboratory Medicine, University of California, San Francisco, San Francisco, California 94143, USA; ²UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, California 94143, USA; ³Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, California 90027, USA; ⁴Department of Pediatrics, Children's Hospital Colorado and University of Colorado School of Medicine, Aurora, Colorado 80045, USA; ⁵Microsoft Research, Redmond, Washington 98052, USA; ⁶Quest Diagnostics Nichols Institute, San Juan Capistrano, California 92675, USA; ⁷Department of Pediatrics, Division of Pediatric Infectious Diseases, Children's National Health System, Washington, DC 20010, USA; ⁸Department of Pediatrics, Microbiology, Immunology, and Tropical Medicine, The George Washington University School of Medicine, Washington, DC 20037, USA; ⁹Department of Medicine, Division of Infectious Diseases, University of California, San Francisco, San Francisco, California 94143, USA

Metagenomic next-generation sequencing (mNGS) for pan-pathogen detection has been successfully tested in proof-of-concept case studies in patients with acute illness of unknown etiology but to date has been largely confined to research settings. Here, we developed and validated a clinical mNGS assay for diagnosis of infectious causes of meningitis and encephalitis from cerebrospinal fluid (CSF) in a licensed microbiology laboratory. A customized bioinformatics pipeline, SURPI+, was developed to rapidly analyze mNGS data, generate an automated summary of detected pathogens, and provide a graphical user interface for evaluating and interpreting results. We established quality metrics, threshold values, and limits of detection of 0.2–313 genomic copies or colony forming units per milliliter for each representative organism type. Gross hemolysis and excess host nucleic acid reduced assay sensitivity; however, spiked phages used as internal controls were reliable indicators of sensitivity loss. Diagnostic test accuracy was evaluated by blinded mNGS testing of 95 patient samples, revealing 73% sensitivity and 99% specificity compared to original clinical test results, and 81% positive percent agreement and 99% negative percent agreement after discrepancy analysis. Subsequent mNGS challenge testing of 20 positive CSF samples prospectively collected from a cohort of pediatric patients hospitalized with meningitis, encephalitis, and/or myelitis showed 92% sensitivity and 96% specificity relative to conventional microbiological testing of CSF in identifying the causative pathogen. These results demonstrate the analytic performance of a laboratory-validated mNGS assay for pan-pathogen detection, to be used clinically for diagnosis of neurological infections from CSF.

[Supplemental material is available for this article.]

Metagenomic next-generation sequencing (mNGS) provides a comprehensive method by which nearly all potential pathogens—viruses, bacteria, fungi, and parasites—can be accurately identified in a single assay (Chiu 2013; Chiu and Miller 2016; Gu et al. 2018; Simner et al. 2018). This approach is attractive for diagnosis of infectious diseases, as pathogens that cause an infectious syndrome commonly have nonspecific, overlapping clinical presentations (Washington 1996). Recent advances in sequencing technology and the development of rapid bioinformatics pipelines have enabled mNGS testing to be performed within a clinically ac-

tionable time frame (Cazanave et al. 2013; Naccache et al. 2014, 2015; Wilson et al. 2014; Frémond et al. 2015; Greninger et al. 2015; Quinn et al. 2016; Salzberg et al. 2016; Mongkolrattanothai et al. 2017; Parize et al. 2017; Schlaberg et al. 2017b). However, numerous challenges remain with migrating mNGS testing into the clinical microbiology laboratory. These include (1) lack of an established blueprint for mNGS clinical validation, (2) difficulty in discriminating pathogens from colonizers or contaminants, (3) paucity of bioinformatics software tailored for clinical diagnostic use, (4) concern over quality and comprehensiveness of available reference databases, and (5) requirement for regulatory compliance

¹⁰These authors contributed equally to this work.

Corresponding author: charles.chiu@ucsf.edu

Article published online before print. Article, supplemental material, and publication date are at <http://www.genome.org/cgi/doi/10.1101/gr.238170.118>. Freely available online through the *Genome Research* Open Access option.

© 2019 Miller et al. This article, published in *Genome Research*, is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at <http://creativecommons.org/licenses/by-nc/4.0/>.

inherent to patient diagnostic testing in a Clinical Laboratory Improvement Amendments (CLIA) environment.

Acute neurological illnesses such as meningitis and encephalitis are devastating syndromes, remaining undiagnosed in a majority of cases (Glaser et al. 2003, 2006; Granerod et al. 2010). The diagnostic workup for many patients requires extensive, and often negative, serial testing that utilizes a combination of culture, antigen, serologic, and molecular methods, resulting in delayed or missed diagnoses and increased costs. Cerebrospinal fluid (CSF) sample volume is often limiting, so that only a fraction of desired tests are able to be performed. Given the high burden of encephalitis-associated hospitalizations in the United States (Khetsuriani et al. 2002), there is a large unmet clinical need for better and more timely diagnostics for this syndrome, both to identify and to exclude infectious etiologies.

Here, we present the development and validation of an mNGS assay for comprehensive diagnosis of infectious causes of meningitis and encephalitis from CSF, expanding on summary data presented in a previously published review (Schlaberg et al. 2017a). The analytic performance of the mNGS assay was compared to results from conventional clinical microbiological testing performed in hospital or commercial diagnostic laboratories. We also tested the assay by blinded retrospective analysis of a challenge set of 20 CSF samples collected from patients with diagnosed neurological infections at a single pediatric tertiary care hospital.

Results

Sample processing and bioinformatics analysis

We developed an mNGS assay for pathogen identification from CSF consisting of library preparation, sequencing, and bioinformatics analysis for pathogen detection (Fig. 1) and validated the performance of the assay in a CLIA-certified laboratory. Standardized operating procedures for the “wet lab” protocols and sequencing runs for this analytic validation study were performed by state-licensed clinical laboratory scientists. For each sequencing run, NTC (“no template” control), PC (positive control), and both RNA and DNA libraries from up to eight patient CSF samples were processed in parallel. Steps included (1) microbial enrichment, (2) nucleic acid extraction, (3) Nextera library construction with two rounds of PCR, (4) library pooling in equimolar concentrations, and (5) rapid-run sequencing on an Illumina instrument, targeting five to 20 million sequences per library (Fig. 1A,B). Raw mNGS sequence data were analyzed using SURPI+, a bioinformatics analysis pipeline for pathogen identification (Naccache et al. 2014) that was modified for clinical use. Specifically, the modified pipeline incorporated filtering algorithms for confirmation of pathogen hits and taxonomic classification for accurate species-level identification.

Results from SURPI+ were tabulated and used to populate a web-based graphical user interface (SURPIviz) designed to facilitate laboratory physician (e.g., microbiologist or pathologist) review and reporting of mNGS findings (Figs. 1C, 2). Results accessible to the laboratory physician included: (1) an automated mNGS results summary in Excel spreadsheet format providing QC run metrics and an overall clinical interpretation (Fig. 2A); (2) heat maps of raw and normalized read counts in each sample (Fig. 2B); (3) individual cells could be interrogated using BLASTn (Altschul et al. 1990) or downloaded in FASTA format for manual downstream analyses; and (4) coverage maps of aligned hits against the most closely matched microbial reference genome or sequence in the

NCBI GenBank nucleotide (nt) database (Fig. 2C). During review of mNGS assay results, the laboratory physician assesses the displayed organism hits for clinical significance, taxonomic specificity, and potential contamination. The SURPIviz graphical tools are used to assist laboratory physicians in preparing a finalized clinical results report that is submitted to the patient electronic medical record (EMR) and available for viewing by treating clinicians (Fig. 2D). The clinical report lists detected organisms by type (virus, bacteria, fungus, or parasite), often with an interpretation and citation of relevant literature.

Establishing thresholds for reporting detected pathogens

To minimize false-positive results from low-level microbial contamination, threshold criteria were established for organism detection (Fig. 1C). For viruses, we developed threshold criteria based on the detection of nonoverlapping reads from ≥ 3 distinct genomic regions. A viral species or genus meeting this threshold was reported as “detected”; otherwise, the virus type (DNA or RNA) was reported as “not detected.” Viruses comprising known body flora, such as anelloviruses (Maggi and Bendinelli 2010; Moustafa et al. 2017) and papillomaviruses (Foulongne et al. 2012), or known laboratory reagent contaminants (Zheng et al. 2011; Salter et al. 2014; Strong et al. 2014; Wilson et al. 2016) were not reported, nor were viruses detected in the NTC and attributed to cross-contamination.

For identification of bacteria, fungi, and parasites, we developed a reads per million (RPM) ratio metric, or RPM-r, defined as $\text{RPM-r} = \text{RPM}_{\text{sample}} / \text{RPM}_{\text{NTC}}$, with the minimum RPM_{NTC} set to 1. This metric accounted for low-level microbial contamination by normalizing detected pathogen reads with respect to the NTC. To determine the optimal threshold value for RPM-r, we plotted receiver operating characteristic (ROC) curves at varying ratios corresponding to mNGS analysis of 95 clinical CSF samples used for accuracy evaluation (Supplemental Fig. S1), showing that an RPM-r of 10 maximized accuracy for organism detection. Thus, a minimum threshold of 10 RPM-r was designated for reporting the detection of a bacterium, fungus, or parasite as “detected” ($\text{RPM-r} \geq 10$) or for reporting the pathogen type as “not detected” ($\text{RPM-r} < 10$).

Limits of detection

To calculate the 95% limits of detection (LOD), defined as the lowest concentration at which 95% of positive samples are detected, we evaluated the PC at concentrations ranging from 0.005 to 5000 genome equivalents/mL across a minimum 4-log dilution range per organism, testing three to 11 replicates at each concentration. Using probit analysis, a 95% limit of detection was determined for each of the seven representative organisms in the PC (Table 1). The final working PC consisted of the seven organisms spiked at concentrations in a range of 0.5- to 2-log above the 95% LOD.

Precision

We demonstrated inter-assay reproducibility by mNGS testing of the NTC and PC across 20 consecutive sequencing runs and intra-assay reproducibility by testing of three independently generated sets of NTC and PC on the same run. Internal spiked phage controls passed QC for every run, and only one PC RNA library (out of 46 DNA and RNA libraries) had fewer than the minimum cutoff of 5 million reads. All seven organisms were detected using




Figure 1. Schematic of the mNGS assay workflow. (A) CSF is extracted after lysis by bead-beating and internal control addition to allow viral, bacterial, fungal, and parasite nucleic acid retrieval. Total nucleic acid extracts are enriched for pathogen DNA by removal of methylated DNA (DNA libraries) and treatment with DNase (RNA libraries). (B) Libraries are generated using the Nextera XT protocol and amplified using two rounds of PCR. Libraries are quantified, pooled, and loaded onto the sequencer. (C) Sequences are processed using SURPI+ software for alignment and classification. Reads are preprocessed by trimming of adapters and removal of low-quality/low-complexity sequences, followed by computational subtraction of human reads and taxonomic classification of remaining microbial reads to family, genus, or species. For viruses, reads are mapped to the closest matched genome to identify nonoverlapping regions; for bacteria, fungi, and parasites, a read per million (RPM) ratio (RPM-r) metric is calculated, defined as $\text{RPM-r} = \text{RPM}_{\text{sample}} / \text{RPM}_{\text{NTC}}$. To aid in analysis, automated result summaries, heat maps of raw/normalized read counts, and coverage/pairwise identity plots are generated for use in review and clinical interpretation.

pre-established threshold criteria for the intra-assay run and each replicate inter-assay run (Table 1).

Accuracy

For evaluation of accuracy, a total of 95 CSF patient samples (73 positive with 79 organisms detected and 22 negative for any pathogen by conventional clinical testing) were tested using the mNGS

assay. A board-certified infectious diseases physician (C.Y.C.) and pathologist (S.M.) independently performed in-depth, retrospective patient chart review to extract the results of conventional clinical testing and final microbiological diagnosis. mNGS results were compared to (1) original clinical test results, (2) results after discrepancy testing, and (3) results after discrepancy testing and exclusion of samples with high host background (Table 1; Fig. 3A, B; Supplemental Table S2).



Table 1. Performance characteristics for the mNGS assay

Performance metric	Method	Results
Limits of detection (LOD) ^a	Qualitative detection of PC dilution replicates by probit analysis Pathogen type DNA virus RNA virus Bacterium, gram-positive Bacterium, gram-negative Fungus, mold Fungus, yeast Parasite Qualitative detection over 20 consecutive PC runs (intra-assay) Qualitative detection of three PC samples on the same run (inter-assay)	Representative organism CMV HIV <i>Streptococcus agalactiae</i> <i>Klebsiella pneumoniae</i> <i>Aspergillus niger</i> <i>Cryptococcus neoformans</i> <i>Toxoplasma gondii</i> 100% concordance 100% concordance 100% concordance
Precision ^a	Qualitative detection of PC held at 4°C for 0, 2, 5, and 6 d	100% concordance
Stability ^a	Qualitative detection of PC subjected to 1, 2, and 3 freeze-thaw cycles	100% concordance
Interference ^a	Qualitative detection of PC with spiked DNA (low, medium, high concentration) Qualitative detection of PC with spiked RNA (low, medium, high concentration) Qualitative detection of PC spiked with hemolytic blood (low, medium, high concentration) Qualitative detection of PC spiked with hemolytic blood (low, medium, high concentration)	DNA RNA DNA RNA All spiked ICs and PC organisms (DNA viruses, bacteria, fungi, parasites) detected above QC thresholds except for DNA spiked into the PC at high concentration ^b All spiked ICs and PC organisms (RNA viruses) detected ^b All spiked ICs and PC organisms (DNA viruses, bacteria, fungi, parasites) detected except for hemolytic blood spiked into the PC at high concentration All spiked ICs and PC organisms (RNA viruses) detected
Accuracy	95 clinical CSF samples, results comparison	Original clinical testing (n = 216 results) After discrepancy testing (n = 217 results) ^c Excluding high background (n = 168 results) ^d
	Pathogen type RNA virus DNA virus Bacterium Fungus Parasite Overall	Sens 67 85 64 71 100 73 Spec 100 100 98 100 99 PPA 86 87 67 83 100 81 NPA 100 100 98 100 99 PPA 85 93 80 90 100 89 NPA 100 100 98 100 100 99


(PC) Positive control mix of seven representative organisms; (IC) spiked internal control consisting of a DNA T1 phage and RNA M2 phage; (mNGS) metagenomic next-generation sequencing; (QC) quality control; (Sens) sensitivity; (Spec) specificity; (PPA) positive percent agreement; (NPA) negative percent agreement.

^aPre-designated QC thresholds included >5 million reads per library, >100 RPM for the spiked ICs, >3 nonoverlapping gene regions for the viruses in the PC, and >10 RPM for the nonviral pathogens in the PC.

^bSpiked DNA at high concentration ($\geq 1 \times 10^5$ cells/mL) resulted in a ~2-log decrease in number of organism reads in the IC and PC.

^cDiscrepancy testing is performed on remaining CSF sample, if available, using molecular methods (i.e., PCR).

^dHigh background is defined as samples with IC RPM < 100.



*Negative clinical results for each of 5 pathogen categories (i.e. DNA virus, RNA virus, bacterium, fungus, or parasite) are aggregated to produce a single comparison of mNGS with clinical testing for each category

Figure 3. Accuracy of mNGS relative to clinical testing of CSF. (A) Flow chart of results from samples evaluated in the accuracy study. Results are separated by organism category (RNA virus, DNA virus, bacterium, fungus, and parasite). Shown are the number of samples positive or negative by clinical testing (first row), agreement between mNGS results and positive clinical results and additional positive detections by mNGS (second row), and, in samples with sufficient remaining volume (third row), the results of orthogonal confirmatory testing (fourth row). (B) 2×2 contingency tables comparing the performance of mNGS relative to clinical testing of CSF. The composite reference standards used are original clinical testing (left), combined original clinical and discrepancy testing (middle), and combined original clinical and discrepancy testing after excluding high host background samples (right). (PPA) Positive predictive agreement, (NPA) negative predictive agreement. (C) 2×2 contingency table showing the results of challenge study. Twenty CSF samples were analyzed by mNGS and compared with the results of conventional clinical testing.

Overall, the mNGS assay showed 73% sensitivity and 99% specificity compared to original clinical test results (Table 1; Fig. 3B, left). Twenty-one cases were initially classified as mNGS false-negatives (Table 2; Supplemental Table S2); eight of 21 had sufficient residual CSF volume available for discrepancy testing. Among these eight mNGS-negative cases, five (two WNV, *Proteus mirabilis*, *Candida parapsilosis*, and *Cryptococcus neoformans*) were negative by follow-up clinical PCR testing and hence reclassified as true-negative cases after discrepancy testing (Table 2; Fig. 3B, middle). Three of eight mNGS-negative cases were positive by follow-up PCR testing and hence considered bona fide mNGS false-negative results. False-negative cases of *Enterococcus gallinarum*

and *Aspergillus fumigatus* were probably missed by mNGS testing because they were high-background samples and weakly positive by original clinical testing (the *E. gallinarum* grew from broth only, and the *A. fumigatus* was galactomannan-positive but fungal culture-negative). A case of *Sporothrix schenckii* was negative by mNGS testing because the full ~32-megabase (Mb) genome of *S. schenckii*, while publicly available (Cuomo et al. 2014), had not yet been deposited in the GenBank nt reference database (March 2015 build) used by SURPI+.

For the remaining 13 mNGS false-negative cases out of 21 that had insufficient volume for follow-up discrepancy testing, we examined the clinical data for potential explanations (Table 2).

Table 2. Discrepant mNGS negative results compared to original clinical testing ($n=21$)

Organism type	Organism detected by original clinical testing	High host background?	Results from original clinical testing	Results from discrepancy testing	Final call	
RNA virus	WNV	N	(+) CSF IgM Ab	(-) WNV PCR	TN	
	WNV	N	(+) CSF IgM Ab	(-) WNV PCR	TN	
	WNV	N	(+) CSF IgM Ab	NT	FN	
DNA virus	EV	N	(+) CSF EV RT-PCR	NT	FN	
	VZV	Y	(+) CSF VZV PCR ^a	NT	FN	
	VZV	Y	(+) CSF VZV PCR ^b	NT	FN	
	EBV	N	(+) CSF EBV PCR ^c	NT	FN	
Bacterium	HSV-2	N	(+) CSF HSV-2 PCR ^c	NT	FN	
	<i>Staphylococcus aureus</i>	Y	(+) Bacterial culture, few organisms	NT	FN	
	<i>S. aureus</i>	Y	(+) Bacterial culture, rare organisms	NT	FN	
	<i>Enterococcus gallinarum</i>	Y	(+) Bacterial culture, growth in broth only	(+) Bacterial 16S rRNA PCR for <i>E. gallinarum</i>	FN	
	<i>Proteus mirabilis</i>	Y	(+) Bacterial culture, rare organisms	(-) Bacterial 16S rRNA PCR	TN	
	<i>Escherichia coli</i>	Y	(+) Bacterial culture, few organisms	NT	FN	
	<i>E. coli</i>	N	(+) Bacterial culture	NT	FN	
	<i>E. coli</i>	Y	(+) Bacterial culture, growth in broth only	NT	FN	
	<i>Acinetobacter baumannii</i>	Y	(+) Bacterial culture, rare organisms	NT	FN	
	<i>Enterobacter cloacae</i>	Y	(+) Bacterial culture, rare organisms	NT	FN	
	Fungus	<i>Candida parapsilosis</i>	N	(+) Bacterial culture, rare organisms	(-) Fungal ITS PCR	TN
		<i>Cryptococcus neoformans</i>	N	(+) CSF CrAg 1:160, (-) fungal culture	(-) Fungal ITS PCR	TN
<i>Aspergillus fumigatus</i>		Y	(+) CSF galactomannan, (-) fungal culture	(+) Fungal ITS PCR for <i>A. fumigatus</i>	FN	
<i>Sporothrix schenckii</i>		N	(+) Culture	(+) Fungal ITS PCR for <i>S. schenckii</i>	FN	

(TN) True-negative; (NT) not tested, as residual sample not available; (FN) false-negative; (Ab) antibody; (rRNA) ribosomal RNA; (PCR) polymerase chain reaction; (CrAg) cryptococcal antigen; (WNV) West Nile virus; (EV) enterovirus; (VZV) varicella-zoster virus; (EBV) Epstein-Barr virus; (HSV-2) herpes simplex virus 2; (ITS) internal transcribed spacer.

^aVZV viral load <251 copies/mL.

^bVZV viral load 1400 copies/mL.

^cPCR C_t (cycle threshold) >37 cycles.

Among six viral cases, one (WNV) had been diagnosed via serology only, and four (two VZV, one EBV, one HSV-2) had low viral loads with high PCR cycle threshold (C_t) values (>37 cycles); two of four additionally had high background. For six of seven missed bacterial cases, cultures recovered few ($n=3$), rare ($n=3$), or broth only growth ($n=1$), with all six being high-background samples.

In 18 cases, additional organisms were detected by mNGS that had not been tested for clinically (Table 3). Nine cases (four HIV, one CMV, two EBV, one HSV-1, one HHV-6) had sufficient CSF sample available for discrepancy testing, and follow-up PCR testing confirmed the positive mNGS results in all nine of these cases, which were reclassified as true-positive cases. Given insufficient CSF volume, the additional organisms detected by mNGS in the nine remaining cases (three HIV, one rotavirus, one rhinovirus, two parvovirus B19, one HHV7, *Bacillus* sp.) could not be independently confirmed by follow-up discrepancy testing. Presumptive evidence of infection from these organisms also could not be documented from patient chart review (serum antibody [Ab] positivity alone in three cases of HIV was not deemed strong enough evidence for CSF viremia). However, mNGS detection of one case of *Bacillus* sp. was classified as false-positive, as it was from a culture-negative CSF sample. Thus, eight of these nine cases overall were excluded from the comparisons, as it could not be determined whether a given additional detection was a true- or false-positive. After discrepancy testing, the mNGS assay overall yielded 81% positive percent agreement and 99% negative percent agreement relative to the combined original and discrepancy testing results (Table 1; Fig. 3B, middle).

A third comparison was performed after exclusion of results from CSF samples with an IC RPM of <100, indicating potential decreased mNGS assay sensitivity due to high background. A total of

26 samples had high background (one RNA virus, three DNA virus, 19 bacteria, two fungi, one negative), and exclusion of these yielded 89% positive percent agreement and 99% negative percent agreement for the mNGS assay overall. Notably, the 19 high-background bacterial samples comprised 70.4% of the total number of culture-positive bacterial cases ($n=27$), consistent with the relatively high leukocyte levels associated with bacterial meningitis.

Seven of the 95 CSF samples in the accuracy study yielded mNGS results with multiple bacterial genera detected, all seven of which were negative by original clinical testing. Detected genera corresponded to low-virulence environmental and/or skin flora organisms not typically associated with cases of meningitis and/or encephalitis (Supplemental Table S2). After clinical chart review, none of these cases were consistent with culture-negative bacterial meningitis, and residual sample was not available for discrepancy testing. Thus, results were attributed to sample contamination, reported as “multiple bacterial genera detected” (with an interpretive comment indicating likely contamination), and considered as negative for pathogen detection by mNGS.

We also evaluated contrived samples consisting of cultures from uncommon pathogenic organisms spiked into negative CSF matrix. All five organisms (*Neisseria meningitidis*, *Streptococcus agalactiae*, *Candida albicans*, *Mycobacterium fortuitum*, *Mycobacterium abscessus*) were correctly detected by mNGS testing.

Interference

We evaluated the effects of interference from human DNA and RNA, red blood cell hemolysis, and mixtures of related species in the same genus (*Staphylococcus aureus* and *Staphylococcus epidermidis*) on mNGS assay performance (Table 1). Addition of exogenous

Table 3. Discrepant mNGS additional positive results compared to original clinical testing ($n = 17$)

Organism type	Additional organism detected by mNGS	Results of discrepancy testing	Ancillary clinical data	Final call
RNA virus	HIV	(+) CSF HIV PCR	(+) HIV serum Ab	TP
	HIV	(+) CSF HIV PCR	(+) HIV serum Ab	TP
	HIV	(+) CSF HIV PCR	(+) HIV serum Ab	TP
	HIV	(+) CSF HIV PCR	(+) HIV serum Ab	TP
	HIV	NT ^a	(+) HIV serum Ab	NT ^a
	HIV	NT ^a	(+) HIV serum Ab	NT ^a
	HIV	NT ^a	(+) HIV serum Ab	NT ^a
	Rhinovirus	NT		NT
	Rotavirus	NT		NT
	CMV	(+) CSF CMV PCR		TP
	DNA virus	Parvovirus B19	NT	
Parvovirus B19		NT		NT
EBV		(+) CSF EBV PCR		TP
EBV		(+) CSF EBV PCR		TP
HSV-1		(+) CSF HSV-1 PCR		TP
HHV-6		(+) CSF HHV-6 PCR		TP
HHV-7		NT		NT
Bacterium		<i>Bacillus</i> sp.	NT	(-) CSF bacterial culture

(TP) True-positive; (NT) not tested, as residual sample not available; (FP) false-positive; (Ab) antibody; (RT-PCR) reverse transcription polymerase chain reaction; (PCR) polymerase chain reaction; (HIV) human immunodeficiency virus; (CMV) cytomegalovirus; (EBV) Epstein-Barr virus; (HSV-1) human simplex virus 1; (HHV-6) human herpesvirus 6.

^aAlthough residual CSF sample was not sufficient for discrepancy testing, positive HIV (+) serum Ab testing supported the mNGS result; however, serologic evidence alone was deemed insufficient to reclassify the result as a true-positive.

DNA at a level $\geq 1 \times 10^5$ cells/mL resulted in an approximately 2-log reduction in the number of IC and PC reads (Supplemental Fig. S2), impairing detection of DNA organisms in the PC. Addition of exogenous DNA at lower levels or RNA did not impact qualitative detection. Based on the interference results, a minimum RPM threshold of 100 was chosen for the IC phage reads, with RPM values below this level indicating that the sample library had high host background, along with an interpretive comment in the mNGS clinical report regarding decreased assay sensitivity for detection of RNA viruses (from RNA libraries) or DNA viruses, bacteria, fungi, and parasites (from DNA libraries).

Available data from 55 CSF samples in the accuracy study were used to evaluate the effect of WBC count, related to the level of host background, on recovery of IC phage sequences. Among 26 samples with IC DNA phage counts of < 100 RPM, indicating high background, the average WBC was 5896 cells/mm³, while 29 samples with IC counts of > 100 RPM had an average WBC count of 27 cells/mm³ ($P = 0.0498$ by two-tailed t -test).

Gross hemolysis (dark red CSF) resulted in decreased sensitivity for RNA virus detection (HIV-1 in the PC) by mNGS but did not affect detection sensitivity for DNA pathogens. Moderate to low levels of hemolysis (pink to light red CSF) did not affect detection sensitivity for any of the PC organisms. Analysis of spiked samples containing *S. aureus* and *S. epidermidis* with equivalent RPM-r values at baseline demonstrated accurate discrimination of species within the same genus when mixed at 1:1, 4:1, and 1:4 ratios, as both species were correctly identified and calculated RPM-r values were within 7% of that expected on the basis of the spiked proportions.

Stability

Analysis of replicates of the PC held at 4°C for 0, 2, 5, and 6 d and subjected to three freeze-thaw cycles demonstrated detection of all organisms (Table 1).

Challenge study

Blinded evaluation of the mNGS assay was performed using a set of 20 CSF samples collected prospectively from pediatric patients hospitalized at Children's Hospital Colorado (CHCO) with meningitis, encephalitis, and/or myelitis (Supplemental Table S3). The overall sensitivity and specificity of mNGS relative to conventional clinical microbiology testing (culture, serology, and/or PCR) were 92% and 96%, respectively. The causative pathogen was correctly identified in 11 of 12 previously positive cases, including cases of enterovirus ($n = 8$), HSV-1 ($n = 1$), HIV-1 ($n = 1$), and WNV ($n = 1$). The mNGS assay failed to detect WNV in a second patient with positive CSF IgM serology. Three additional organisms (*Enterobacter* sp., *Corynebacterium* sp., and EBV) were detected by mNGS testing, each from a different sample. The detection of *Enterobacter* sp. and *Corynebacterium* sp. were classified as false-positives, since the two samples had previously tested negative by CSF culture. The patient with positive CSF mNGS testing for EBV was also positive for EBV IgG antibodies in blood; however, this finding was excluded from the comparison due to the lack of residual CSF sample volume for confirmation. In addition, mNGS failed to detect organisms in four cases presumptively diagnosed by testing at sites other than CSF, including one case of *Borrelia burgdorferi* (blood serology), two cases of *Mycoplasma* encephalitis (PCR-positive respiratory but PCR-negative CSF samples), and one case of enterovirus 71 infection (positive rectal swab culture but negative CSF PCR). These four cases were also excluded from the comparison, as the diagnosis had not been made directly from CSF. Negative mNGS results were concordant with negative clinical testing in four undiagnosed cases, including one case of culture-negative bacterial meningitis and three cases of idiopathic encephalitis.

Discussion

We developed and analytically validated a clinical CSF mNGS assay intended to aid in the diagnosis of infectious etiologies of

meningitis, encephalitis, and/or myelitis in hospitalized patients. The mNGS assay has been subsequently evaluated for clinical utility in a 1-yr prospective diagnostic trial in hospitalized patients presenting acutely with suspected neurological infection (Wilson et al. 2019). As CSF is considered a normally sterile site, we postulated that interpretation of CSF mNGS data would be more straightforward than data from nonsterile sites such as respiratory secretions and stool. However, numerous challenges had to be overcome for successful implementation of mNGS for broad-spectrum pathogen detection in the clinical laboratory. First, a universal sequencing library preparation protocol employing two rounds of PCR was developed, robust across the wide range of human host background seen in patient CSF (0–10⁸ leukocytes/mm³). Second, QC materials were incorporated, including external PC and NTC samples that are run in parallel with CSF samples, as well as internally spiked RNA and DNA controls. Third, reproducible threshold metrics were established and evaluated using ROC curve analysis to enable correct identification of pathogens from mNGS data above background noise and minimize false-positive results. The final clinical mNGS protocol incorporated (1) a bead-beating step for complete lysis of microbial cell walls, (2) separate construction of RNA and DNA libraries from nucleic acid extracts for detection of RNA viruses and DNA-based microorganisms, respectively, and (3) SURPI+ bioinformatics analysis using the entirety of the NCBI GenBank nt database as a comprehensive reference database.

Our clinical mNGS library preparation protocol uses a transposon-based approach (Nextera). A key advantage of this approach is the ease of use and rapid turnaround time for the protocol, which is amenable to routine clinical laboratory workflows. This method has been shown to exhibit a GC bias with respect to sequenced reads (Lan et al. 2015). However, here we tested representative organisms with GC content ranging from 35.4% to 57.4%, core genomes tend to have a lower GC bias (Bohlin et al. 2018), and detection by mNGS remains possible from less-biased genomic regions. Of note, we have not observed an appreciable difference in mNGS assay sensitivity using adapter ligation-based kits (Naccache et al. 2014; Luk et al. 2015). Nevertheless, further studies will be needed to establish whether mNGS is able to detect organisms at the extremes of GC content.

Based on the PC mix of seven representative organisms, assay limits of detection ranged from 0.2 CFU/mL for *C. neoformans* to 313 copies/mL for HIV. Metagenomic sensitivity for detection of a given organism is dependent on a number of factors, including extraction efficiency, size of the genome, library preparation bias, and availability of matching reference genomes in the database. We believe that *C. neoformans* was detected at lower levels due to a number of factors. The relative large eukaryotic genome size (~19 Mb) increases the amount of pathogen relative to human DNA, even for low numbers of organisms. *C. neoformans* may also be more susceptible to lysis than organisms with more rigid cell walls such as *Aspergillus niger*, so that more DNA may be released after bead-beating and hence available for sequencing. In addition, the complete sequences of all 14 *C. neoformans* chromosomes were available in the NCBI GenBank nt database (March 2015 build) used by SURPI+, unlike for *Toxoplasma gondii*, with only representation of a limited subset of genes or gene regions.

Given the untargeted nature of mNGS, a key limitation for infectious disease diagnostics is background interference, generally from human host DNA. In addition to controlling for nucleic acid extraction efficiency, the use of a spiked phage IC was found to be useful for assessing whether high host background was pre-

sent, indicating decreased sensitivity of pathogen detection by mNGS. Overall, 27.4% of DNA libraries and 6.3% of RNA libraries in the accuracy study had fewer than 100 RPM IC phage reads recovered, making background interference a fairly common limitation. Thus, in high-background samples, negative mNGS findings may be less useful for excluding infection, and other diagnostic tests that are less sensitive to background should be considered, such as 16S rRNA bacterial PCR (Salipante et al. 2013) and ITS fungal PCR (Pryce et al. 2006). This is especially relevant in cases of bacterial meningitis with high leukocyte counts in CSF. Despite this limitation, mNGS was still able to detect bacterial pathogens in 12 of 19 culture-positive samples in the accuracy study with high host background.

The overall accuracy of the mNGS assay for pathogen detection relative to conventional clinical testing was 90%, with 73% sensitivity and 99% specificity. The calculated 73% sensitivity refers to clinical sensitivity—sensitivity in diagnosis of infection, and not analytical sensitivity—sensitivity in detection of pathogen nucleic acid. Factors impacting the clinical sensitivity of mNGS include (1) cases diagnosed only by serology (e.g., WNV), (2) use of clinical testing as an imperfect “gold standard,” with some samples possibly representing false-positive detections from contamination (e.g., *Enterococcus faecalis* with growth from broth only), (3) analysis of remnant biobanked clinical samples for mNGS accuracy testing, with degradation from prior freeze-thaw steps likely decreasing sensitivity, (4) use of robust pre-established thresholds to minimize false-positive detections, and (5) role of human host background (e.g., high CSF pleocytosis) in limiting sensitivity. Among the eight of 21 mNGS false-negative cases with sufficient remaining CSF volume, follow-up discrepancy PCR testing was negative for five of eight (62.5%), suggesting that sample degradation may have occurred over time or that the original clinical result was incorrect. Indeed, positive percent agreement rose to 81% after discrepancy testing of samples with sufficient volume, and exclusion of samples with high host background increased this further to 89%.

Only a fraction of all possible diagnostic tests for pathogens are performed in clinical microbiology laboratories given cost, limited CSF sample volume, and long turnaround times for reference (send out) laboratory testing. We decided to exclude additional organism detections by mNGS ($n=18$) in the initial assessment of specificity, as no clinical reference result was available. However, in nine cases out of 18 with sufficient CSF volume for discrepancy testing, all nine were found to be analytical true-positives. Furthermore, an additional three cases had peripheral blood serology results consistent with neurological infection by the organism detected by mNGS (Table 3). Thus, at least 12 of 18 (66.7%) additional organisms identified by mNGS are likely true-positive detections, with only one of 18 (5.6%), a culture-negative case positive by mNGS for *Bacillus* sp., classified as a false-positive.

As with any diagnostic assay, mNGS testing is prone to contamination. Often, the identity of the species detected can provide clues as to the contamination source, such as skin flora (e.g., *S. epidermidis*, papillomaviruses), laboratory reagents (murine gammaretroviruses, *E. coli*, insect viruses), body flora (e.g., anelloviruses), or environmental flora (e.g., *Thermus* sp., *Bacillus* sp.). Cross-contamination in particular is a major concern given that the mNGS protocol involves PCR amplification. Strict processing controls to minimize contamination are essential and include unidirectional workflow, positive pressure ventilation in pre-amplification areas, and workspace separation for different assay steps. To monitor for contamination, we also developed standardized

protocols for QC testing of new reagents and periodic swipe testing of instruments and laboratory surfaces (Supplemental Methods). Continual tracking of contaminants seen in the NTC or PC is also done, and conservative threshold criteria are used to minimize the reporting of false-positive results. The development and use of ultraclean reagents with no or extremely low levels of DNA contamination may also help in minimizing assay contamination (Motley et al. 2014).

Approximately 7% of the clinical samples in the accuracy study had multiple bacterial genera detected above pre-established thresholds, generally consisting of environmental or skin flora. The challenge of determining the clinical significance of detecting organisms that may be contaminants is a classical problem in clinical microbiology and often requires clinical context for interpretation. As CSF is a normally sterile site, rarely are bacterial or fungal co-infections causative for cases of meningitis or encephalitis, with the possible exception of foreign body infections or polymicrobial brain abscesses communicating with CSF (Martin et al. 2018). Thus, detection of multiple bacterial and/or fungal genera are noted in the mNGS results report as probable sample contamination and were considered negative in our evaluation of assay performance.

The challenge study evaluated CSF mNGS testing as a first-line diagnostic assay for neurological infections and demonstrated that mNGS detected the same organism identified via conventional microbiological testing of CSF in 11 of 12 (91.7%) cases. The missed case of WNV was diagnosed by serologic IgM testing of CSF. This case and a presumptive Lyme disease case diagnosed by serologic testing of peripheral blood underscore the critical dependence of mNGS detection on the presence of nucleic acid from the organism at the time of sample collection. As a direct detection method, mNGS can miss infections that are often only successfully diagnosed using serology (e.g., WNV, Lyme neuroborreliosis, and neurosyphilis), given that the causative pathogen may be absent or only transiently present in CSF. For these cases, direct detection testing approaches such as PCR and mNGS lack sensitivity, and there should be a low threshold for indirect serologic testing or laboratory testing from other body sites to establish the diagnosis (DeBiasi and Tyler 2004).

While mNGS testing can provide broad-spectrum pathogen identification, assessment of the clinical significance of the reported findings may require interpretation. Direct discussions or teleconferences can be set up with treating clinicians to clarify and review mNGS results in clinical context. These forums can also be used to communicate results of secondary analyses of mNGS data, including (1) genome assembly for characterization of predicted antibiotic or antiviral resistance mutations, (2) phylogenetic analysis for genotyping and strain-level identification, and (3) disclosure of reads from potential pathogens below formal reporting thresholds. Thus, the clinical relevance of mNGS findings can be efficiently communicated to physicians, potentially informing the next steps in management and treatment of the patient, and may also prove informative for public health surveillance and outbreak investigation (Chiu et al. 2017).

Methods

mNGS assay

We developed standard operating procedures (SOPs) in the clinical laboratory for processing and analyzing CSF samples by mNGS. Each of the “wet lab” and bioinformatics processing steps was op-

timized to ensure sensitive and accurate organism detection (Schlaberg et al. 2017a). The mNGS assay workflow was performed as follows (Fig. 1), with a more detailed description provided in the Supplemental Methods. Briefly, each CSF sample was first subjected to bead-beating to lyse organisms (Fig. 1A), followed by addition (“spiking”) of T1 (DNA) and MS2 (RNA) bacteriophages as an internal control (IC). Total nucleic acid was then extracted and split into two aliquots for construction of separate DNA and RNA libraries. Microbial sequences were enriched by antibody-based removal of methylated host DNA (for DNA libraries) or DNase treatment (for RNA libraries), followed by transposon-based library construction (Fig. 1B). Each sequencing run on an Illumina HiSeq instrument included up to eight samples, along with a negative “no template” control consisting of elution buffer, intended to allow for sensitive detection of contamination, and a positive control consisting of a mixture of seven representative pathogenic organisms (RNA virus, DNA virus, Gram-positive bacterium, Gram-negative bacterium, fungus, mold, and parasite).

Sequence analysis was performed using the SURPI+ computational pipeline (Fig. 1C; Supplemental Methods), an automated clinical version of the previously published SURPI (“sequence-based ultrarapid pathogen identification”) research pipeline (Naccache et al. 2014). Receiver-operator curve analyses were performed as part of the accuracy study to determine optimal threshold values for organism detection (Supplemental Methods), using 95 clinical CSF samples with established microbiological results. These pre-established thresholds were then finalized and used for all subsequent clinical mNGS runs. Each mNGS run was analyzed by experienced laboratory physicians (S.M. and C.Y.C.), and results were generated for five categories per sample (RNA virus, DNA virus, bacteria, fungi, and parasite). Run quality control (QC) metrics included a minimum of 5 million reads per library, ≥ 100 reads per million for the IC T1 and MS2 phages in the DNA and RNA libraries, respectively, and positive qualitative detection of each of the seven organisms in the PC.

Evaluation of mNGS analytical performance characteristics

A detailed description of the methods used to evaluate mNGS analytical performance characteristics is provided in the Supplemental Methods. Briefly, limits of detection were determined for each of the seven representative organisms in the PC by probit analysis using a series of dilutions across a minimum 4-log range. Precision was determined using repeat analysis of the PC and NTC over 20 consecutive sequencing runs (inter-assay reproducibility) and three sets of separate PCs and NTCs processed in parallel on the same run (intra-assay reproducibility). Test stability was determined using control samples held at various temperatures and subject to multiple freeze/thaw cycles. Interference was determined using PC spiked with known amounts of human DNA or RNA material. Results were assessed for qualitative detection of organisms in the PC.

Accuracy was determined using 95 clinical CSF samples comprising 73 positive samples containing 79 detected organisms in total and 22 negative samples (Fig. 3A). Samples were obtained from patients at the University of California, San Francisco (UCSF) ($n=59$), Children’s National Medical Center (CNMC) ($n=19$), Children’s Hospital Colorado (CHCO) ($n=1$), and Quest Diagnostics ($n=16$). Three composite reference standards were generated for comparisons of mNGS assay performance with “gold standard” clinical microbiological testing (Fig. 3B): (1) original clinical testing results; (2) combined results from original clinical testing and additional discrepancy testing of initial false-negative or false-positive samples for which sufficient residual CSF volume was available; and (3) original and discrepancy testing

results after exclusion of samples with high background corresponding to the human host (see “Interference,” above). The second and third comparisons are reported as positive percent agreement (PPA) and negative percent agreement (NPA), as selective discrepancy testing can bias estimates of test sensitivity and specificity (U.S. Food and Drug Administration 2007). To evaluate mNGS detection performance for additional organism types not readily available from clinical CSF samples, the accuracy study also included mNGS testing of contrived samples of five known organisms (*N. meningitidis*, *S. agalactiae*, *C. albicans*, *M. fortuitum*, *M. abscessus*) spiked into negative CSF at defined concentrations.

Challenge study

The Aseptic Meningitis and Encephalitis Study (AMES) is a prospective cohort study enrolling children presenting to CHCO with culture-negative meningitis and encephalitis since 2012. A subset of CSF samples ($n=20$) with sufficient residual volume of 600 μ L from subjects with known and unknown etiologies was coded for mNGS testing as a challenge set. Samples were processed in a blinded fashion at UCSF and results discussed in clinical context with site investigators at CHCO over web-based teleconferencing.

Software availability

The SURPI+ computational pipeline software used by the UCSF clinical CSF mNGS assay consists of publicly available source code and proprietary binaries and is available for download on GitHub (<https://github.com/chiulab/SURPI-plus-dist>). Shell scripts to reconstruct the essential NCBI GenBank nt reference databases using the alignment programs (SNAP [Naccache et al. 2014], Bowtie 2 [Langmead and Salzberg 2012], and BLASTn [Altschul et al. 1990]) are also provided in this distribution. Note that the databases used are from the March 2015 distribution of GenBank nt and use GI instead of accession numbers. The source code includes the following external open-source tools: BLAST v2.7.1 (Altschul et al. 1990), Bowtie 2 v2.3.2 (Langmead and Salzberg 2012), cutadapt v1.2.1 (Martin 2011), PRINSEQ-lite v0.20.3 (Schmieder and Edwards 2011), and SNAP v0.15.4 (Naccache et al. 2014).

Data access

Metagenomic reads from patient CSF samples from this study were depleted of human host sequences and have been submitted to the NCBI BioProject database (<https://www.ncbi.nlm.nih.gov/bioproject>) under accession number PRJNA516289. Sequences corresponding to the HIV-1 and CMV controls in the PC and the MS2 (RNA) phage and T1 (DNA) phage spiked IC samples from this study have been submitted to NCBI GenBank (<https://www.ncbi.nlm.nih.gov/genbank/>) under accession numbers MK214316, MK213797, MK213795, and MK213796, respectively.

Competing interest statement

C.Y.C. is the director of the UCSF-Abbott Viral Diagnostics and Discovery Center (VDDC) and receives research support from Abbott Laboratories, Inc. C.Y.C., S.A., D.S., S.F., and S.M. are inventors on a patent application on algorithms related to SURPI+ software titled “Pathogen Detection using Next-Generation Sequencing” (PCT/US/16/52912).

Acknowledgments

We thank the staff of the UCSF Clinical Immunology lab for their help in discrepancy testing and Gail Cunningham for her expert help in obtaining AFB organisms. We also thank Brittany Goldberg at CNMC for providing clinical samples for use in the validation. This work is supported by National Institutes of Health (NIH) grants R01 HL105704 and R21/R33 AI120977 (C.Y.C.), a UC Center for Accelerated Innovation grant funded by NIH grant U54 HL119893 and NIH NCATS UCSF-CTSI grant UL1 TR000004 (C.Y.C.), the California Initiative to Advance Precision Medicine (C.Y.C. and S.M.), research support from Abbott Laboratories, Inc. (C.Y.C.), and supplemental funding from the UCSF Medical Center (C.Y.C. and S.M.).

Author contributions: C.Y.C., S.M., E.S., and S.N.N. developed the project. E.S., E.P., S.A., B.F., and W.L. generated libraries. S.N.N., S.M., and C.Y.C. analyzed data for clinical validation. S.F., D.S., and C.Y.C. developed SURPI+ software and a graphical user interface for clinical use. W.J.B. modified the SNAP algorithm to facilitate taxonomic classification by SURPI+, and S.M.P. banked CSF samples. J.A.L., S.D., K.M., S.M., and C.Y.C. provided clinical specimens. K.M., S.D., J.A.L., S.N.N., S.M.P., C.Y.C., and S.M. conducted chart review. D.L., B.F., and S.A. conducted discrepancy testing. S.M., S.N.N., and C.Y.C. wrote the manuscript with contributions from all authors.

References

- Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. 1990. Basic local alignment search tool. *J Mol Biol* **215**: 403–410. doi:10.1016/S0022-2836(05)80360-2
- Bohlin J, Eldholm V, Brynildsrud O, Petterson JH, Alfsnes K. 2018. Modeling of the GC content of the substituted bases in bacterial core genomes. *BMC Genomics* **19**: 589. doi:10.1186/s12864-018-4984-3
- Cazanave C, Greenwood-Quaintance KE, Hanssen AD, Karau MJ, Schmidt SM, Gomez Urena EO, Mandrekar JN, Osmon DR, Lough LE, Pritt BS, et al. 2013. Rapid molecular microbiologic diagnosis of prosthetic joint infection. *J Clin Microbiol* **51**: 2280–2287. doi:10.1128/JCM.00335-13
- Chiu CY. 2013. Viral pathogen discovery. *Curr Opin Microbiol* **16**: 468–478. doi:10.1016/j.mib.2013.05.001
- Chiu C, Miller S. 2016. Next-generation sequencing. In *Molecular microbiology: diagnostic principles and practice*, 3rd ed. (ed. Persing DH, et al.), pp. 68–79. ASM Press, Washington, DC.
- Chiu CY, Coffey LL, Murkey J, Symmes K, Sample HA, Wilson MR, Naccache SN, Arevalo S, Somasekar S, Federman S, et al. 2017. Diagnosis of fatal human case of St. Louis encephalitis virus infection by metagenomic sequencing, California, 2016. *Emerg Infect Dis* **23**: 1964–1968. doi:10.3201/eid2310.161986
- Cuomo CA, Rodriguez-Del Valle N, Perez-Sanchez L, Abouelleil A, Goldberg J, Young S, Zeng Q, Birren BW. 2014. Genome sequence of the pathogenic fungus *Sporothrix schenckii* (ATCC 58251). *Genome Announc* **2**: e00446-14. doi:10.1128/genome.A.00446-14
- DeBiasi RL, Tyler KL. 2004. Molecular methods for diagnosis of viral encephalitis. *Clin Microbiol Rev* **17**: 903–925. doi:10.1128/CMR.17.4.903-925.2004
- Foulongne V, Sauvage V, Hebert C, Dereure O, Cheval J, Gouilh MA, Pariente K, Segondy M, Burguière A, Manuguerra JC, et al. 2012. Human skin microbiota: high diversity of DNA viruses identified on the human skin by high throughput sequencing. *PLoS One* **7**: e38499. doi:10.1371/journal.pone.0038499
- Frémond ML, Pérot P, Muth E, Cros G, Dumarest M, Mahlaoui N, Seilhean D, Desguerre I, Hébert C, Corre-Catelin N, et al. 2015. Next-generation sequencing for diagnosis and tailored therapy: a case report of astrovirus-associated progressive encephalitis. *J Pediatric Infect Dis Soc* **4**: e53–e57. doi:10.1093/jpids/piv040
- Glaser CA, Gilliam S, Schnurr D, Forghani B, Honarmand S, Khetsuriani N, Fischer M, Cossen CK, Anderson LJ, California Encephalitis Project 1998–2000. 2003. In search of encephalitis etiologies: diagnostic challenges in the California Encephalitis Project, 1998–2000. *Clin Infect Dis* **36**: 731–742. doi:10.1086/367841
- Glaser CA, Honarmand S, Anderson LJ, Schnurr DP, Forghani B, Cossen CK, Schuster FL, Christie LJ, Tureen JH. 2006. Beyond viruses: clinical profiles and etiologies associated with encephalitis. *Clin Infect Dis* **43**: 1565–1577. doi:10.1086/509330

- Granerod J, Ambrose HE, Davies NW, Clewley JP, Walsh AL, Morgan D, Cunningham R, Zuckerman M, Mutton KJ, Solomon T, et al. 2010. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. *Lancet Infect Dis* **10**: 835–844. doi:10.1016/S1473-3099(10)70222-X
- Greninger AL, Messacar K, Dunnebacke T, Naccache SN, Federman S, Bouquet J, Mirsky D, Nomura Y, Yagi S, Glaser C, et al. 2015. Clinical metagenomic identification of *Balamuthia mandrillaris* encephalitis and assembly of the draft genome: the continuing case for reference genome sequencing. *Genome Med* **7**: 113. doi:10.1186/s13073-015-0235-2
- Gu W, Miller S, Chiu CY. 2018. Clinical metagenomic next-generation sequencing for pathogen detection. *Annu Rev Pathol* **14**: 319–338. doi:10.1146/annurev-pathmechdis-012418-012751.
- Khetsuriani N, Holman RC, Anderson LJ. 2002. Burden of encephalitis-associated hospitalizations in the United States, 1988–1997. *Clin Infect Dis* **35**: 175–182. doi:10.1086/341301
- Lan JH, Yin Y, Reed EF, Moua K, Thomas K, Zhang Q. 2015. Impact of three Illumina library construction methods on GC bias and HLA genotype calling. *Hum Immunol* **76**: 166–175. doi:10.1016/j.humimm.2014.12.016
- Langmead B, Salzberg SL. 2012. Fast gapped-read alignment with Bowtie 2. *Nat Methods* **9**: 357–359. doi:10.1038/nmeth.1923
- Luk KC, Berg MG, Naccache SN, Kabre B, Federman S, Mbanya D, Kaptué L, Chiu CY, Brennan CA, Hackett J Jr. 2015. Utility of metagenomic next-generation sequencing for characterization of HIV and human papillomavirus diversity. *PLoS One* **10**: e0141723. doi:10.1371/journal.pone.0141723
- Maggi F, Bendinelli M. 2010. Human anelloviruses and the central nervous system. *Rev Med Virol* **20**: 392–407. doi:10.1002/rmv.668
- Martin M. 2011. Cutadapt removes adapter sequences from high-throughput sequencing reads. *EMBnetjournal* **17**. doi:10.14806/ej.17.1.200
- Martin RM, Zimmermann LL, Huynh M, Polage CR. 2018. Diagnostic approach to health care- and device-associated central nervous system infections. *J Clin Microbiol* **56**: e00861-18. doi:10.1128/JCM.00861-18
- Mongkolrattanothai K, Naccache SN, Bender JM, Samayoa E, Pham E, Yu G, Dien Bard J, Miller S, Aldrovandi G, Chiu CY. 2017. Neurobrucellosis: unexpected answer from metagenomic next-generation sequencing. *J Pediatric Infect Dis Soc* **6**: 393–398. doi:10.1093/jpids/piw066
- Motley ST, Picuri JM, Crowder CD, Minich JJ, Hofstadler SA, Eshoo MW. 2014. Improved multiple displacement amplification (iMDA) and ultra-clean reagents. *BMC Genomics* **15**: 443. doi:10.1186/1471-2164-15-443
- Moustafa A, Xie C, Kirkness E, Biggs W, Wong E, Turpaz Y, Bloom K, Delwart E, Nelson KE, Venter JC, et al. 2017. The blood DNA virome in 8,000 humans. *PLoS Pathog* **13**: e1006292. doi:10.1371/journal.ppat.1006292
- Naccache SN, Federman S, Veeraraghavan N, Zaharia M, Lee D, Samayoa E, Bouquet J, Greninger AL, Luk KC, Enge B, et al. 2014. A cloud-compatible bioinformatics pipeline for ultrarapid pathogen identification from next-generation sequencing of clinical samples. *Genome Res* **24**: 1180–1192. doi:10.1101/gr.171934.113
- Naccache SN, Peggs KS, Mattes FM, Phadke R, Garson JA, Grant P, Samayoa E, Federman S, Miller S, Lunn MP, et al. 2015. Diagnosis of neuroinvasive astrovirus infection in an immunocompromised adult with encephalitis by unbiased next-generation sequencing. *Clin Infect Dis* **60**: 919–923. doi:10.1093/cid/ciu912
- Parize P, Muth E, Richaud C, Gratigny M, Pilmis B, Lamamy A, Mainardi JL, Cheval J, de Visser L, Jagorel F, et al. 2017. Untargeted next-generation sequencing-based first-line diagnosis of infection in immunocompromised adults: a multicentre, blinded, prospective study. *Clin Microbiol Infect* **23**: 574. doi:10.1016/j.cmi.2017.02.006
- Pryce TM, Palladino S, Price DM, Gardam DJ, Campbell PB, Christiansen KJ, Murray RJ. 2006. Rapid identification of fungal pathogens in Bact/ALERT, BACTEC, and BBL MGIT media using polymerase chain reaction and DNA sequencing of the internal transcribed spacer regions. *Diagn Microbiol Infect Dis* **54**: 289–297. doi:10.1016/j.diagmicrobio.2005.11.002
- Quinn RA, Navas-Molina JA, Hyde ER, Song SJ, Vazquez-Baeza Y, Humphrey G, Gaffney J, Minich JJ, Melnik AV, Herschend J, et al. 2016. From sample to multi-omics conclusions in under 48 hours. *mSystems* **1**: e00038-16. doi:10.1128/mSystems.00038-16
- Salipante SJ, Sengupta DJ, Rosenthal C, Costa G, Spangler J, Sims EH, Jacobs MA, Miller SI, Hoogstraal DR, Cookson BT, et al. 2013. Rapid 16S rRNA next-generation sequencing of polymicrobial clinical samples for diagnosis of complex bacterial infections. *PLoS One* **8**: e65226. doi:10.1371/journal.pone.0065226
- Salter SJ, Cox MJ, Turek EM, Calus ST, Cookson WO, Moffatt MF, Turner P, Parkhill J, Loman NJ, Walker AW. 2014. Reagent and laboratory contamination can critically impact sequence-based microbiome analyses. *BMC Biol* **12**: 87. doi:10.1186/s12915-014-0087-z
- Salzberg SL, Breitwieser FP, Kumar A, Hao H, Burger P, Rodriguez FJ, Lim M, Quiñones-Hinojosa A, Gallia GL, Tornheim JA, et al. 2016. Next-generation sequencing in neuropathologic diagnosis of infections of the nervous system. *Neurol Neuroimmunol Neuroinflamm* **3**: e251. doi:10.1212/NXI.0000000000000251
- Schlalberg R, Chiu CY, Miller S, Procop GW, Weinstock G; Professional Practice Committee and Committee on Laboratory Practices of the American Society for Microbiology; Microbiology Resource Committee of the College of American Pathologists. 2017a. Validation of metagenomic next-generation sequencing tests for universal pathogen detection. *Arch Pathol Lab Med* **141**: 776–786. doi:10.5858/arpa.2016-0539-RA
- Schlalberg R, Queen K, Simmon K, Tardif K, Stockmann C, Flygare S, Kennedy B, Voelkerding K, Bramley A, Zhang J, et al. 2017b. Viral pathogen detection by metagenomics and pan-viral group polymerase chain reaction in children with pneumonia lacking identifiable etiology. *J Infect Dis* **215**: 1407–1415. doi:10.1093/infdis/jix148
- Schmieder R, Edwards R. 2011. Quality control and preprocessing of metagenomic datasets. *Bioinformatics* **27**: 863–864. doi:10.1093/bioinformatics/btr026
- Simner PJ, Miller S, Carroll KC. 2018. Understanding the promises and hurdles of metagenomic next-generation sequencing as a diagnostic tool for infectious diseases. *Clin Infect Dis* **66**: 778–788. doi:10.1093/cid/cix881
- Strong MJ, Xu G, Morici L, Splinter Bon-Durant S, Baddoo M, Lin Z, Fewell C, Taylor CM, Flemington EK. 2014. Microbial contamination in next generation sequencing: implications for sequence-based analysis of clinical samples. *PLoS Pathog* **10**: e1004437. doi:10.1371/journal.ppat.1004437
- U.S. Food and Drug Administration. 2007. *Guidance for industry and FDA staff: statistical guidance on reporting results from studies evaluating diagnostic tests*. U.S. Food and Drug Administration, Silver Spring, MD. <https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm071287.pdf>.
- Washington JA. 1996. Principles of diagnosis. In *Medical microbiology*, 4th ed. (ed. Baron S). University of Texas Medical Branch at Galveston, Galveston, TX.
- Wilson MR, Naccache SN, Samayoa E, Biagtan M, Bashir H, Yu G, Salamat SM, Somasekar S, Federman S, Miller S, et al. 2014. Actionable diagnosis of neuroleptospirosis by next-generation sequencing. *N Engl J Med* **370**: 2408–2417. doi:10.1056/NEJMoa1401268
- Wilson MR, Fedewa G, Stenglein MD, Olejnik J, Rennick LJ, Nambulli S, Feldmann F, Duprex WP, Connor JH, Mühlberger E, et al. 2016. Multiplexed metagenomic deep sequencing to analyze the composition of high-priority pathogen reagents. *mSystems* **1**: e00058-16. doi:10.1128/mSystems.00058-16
- Wilson MR, Sample HA, Zorn KC, Arevalo S, Yu G, Neuhaus J, Federman S, Stryke D, Briggs B, Langelier C, et al. 2019. Clinical metagenomic next-generation sequencing for diagnosis of infectious meningitis and encephalitis. *N Engl J Med* (in press).
- Zheng H, Jia H, Shankar A, Heneine W, Switzer WM. 2011. Detection of murine leukemia virus or mouse DNA in commercial RT-PCR reagents and human DNAs. *PLoS One* **6**: e29050. doi:10.1371/journal.pone.0029050

Received April 6, 2018; accepted in revised form February 25, 2019.